Haemonetics (NYSE:HAE) announced today that it purchased the technology underlying the TEG 6s hemostasis analyzer system from CoraMed Technologies.
Braintree, Mass.-based Haemonetics now owns the intellectual property it previously licensed from CoraMed for use in hospitals and hospital laboratories, and may pursue site-of-care opportunities beyond hospitals.
TEG 6s includes an analyzer, disposable cartridges and software designed to identify a patient’s hemostasis condition. It has FDA clearance for use with adults in cardiovascular surgery, cardiology procedures and most recently won an expanded indication for adult trauma in May 2019.
Haemonetics has touted the TEG 6s as the first cartridge-based system available in the U.S. to evaluate hemostasis conditions in adult trauma patients. The system also has CE Mark approval and other international clearance for adults for whom an evaluation of blood coagulation properties is desired, according to a news release.
“This acquisition is another step forward in our plans to accelerate growth in our hospital business and execute against our customer-focused strategies,” Haemonetics global hospital president Stew Strong said in the news release. “We now have the ability to explore potential new channels for the TEG 6s system both in hospitals as well as outside of hospitals. … We have had a long, productive relationship with CoraMed and its founders, who are recognized experts in their field, and we are pleased that we are able to continue advancing the TEG 6s system’s presence in the market.”